The Almond Yogurt Study (AYS) (AYS)

November 16, 2026 updated by: Amanda Wright, Ph.D., University of Guelph

The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.

Study Overview

Detailed Description

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

Study Type

Interventional

Enrollment (Estimated)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ontario
      • Guelph, Ontario, Canada, N1G 2G4
        • Department of Human Health Sciences
        • Contact:
        • Contact:
          • Alison M Duncan, PhD
        • Principal Investigator:
          • Amanda J Wright, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy female adults aged 18-45 years.
  • Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or post-menopausal

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Whole - Chopped - Buttered

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Whole - Buttered - Chopped

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Buttered - Whole - Chopped

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Buttered - Chopped - Whole

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Chopped - Buttered - Whole

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Experimental: Chopped - Whole - Buttered

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastric emptying half-time
Time Frame: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eating time
Time Frame: From 0 minutes until the end of eating the breakfast meal

The time to consume the breakfast meal based on video recordings, in minutes

From 0 minutes until the end of eating the breakfast meal
Changes from baseline in postprandial satiety visual analogue scale ratings
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma triacylglycerol concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/L

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Triacylglycerol response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma GLP-1 concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pg/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
GLP-1 response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma CCK concentration
Time Frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/L

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
CCK response - incremental area under the curve (AUC)
Time Frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in gastric volume
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Gastric volume - incremental area under the curve (AUC)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Borg rating of perceived exertion
Time Frame: Immediately after the breakfast meal is consumed

Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

Immediately after the breakfast meal is consumed
Changes from baseline in plasma blood glucose concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Glucose response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma blood insulin concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Insulin response - Area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Product liking and perceived attributes
Time Frame: Immediately after eating the breakfast meal

Participant paper scale questionnaire ratings

Immediately after eating the breakfast meal
Eating rate
Time Frame: From 0 minutes until the end of eating the breakfast meal

Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

From 0 minutes until the end of eating the breakfast meal
Number of chews
Time Frame: From 0 minutes until the end of eating the breakfast meal

Determined by count from video recordings of each eating session

From 0 minutes until the end of eating the breakfast meal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

December 15, 2027

Study Completion (Estimated)

December 19, 2027

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ID3014
  • 400819 (Other Grant/Funding Number: Natural Sciences & Engineering Research Council of Canada)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe